Introduction
Pyrethroids are a class of insecticides analogous to the natural pyrethrins found in the chrysanthemum family (Tan and Soderlund, 2010; Breckenridge et al., 2009) . Safer than their organophosphate predecessors, pyrethroids have become the most popular class of insecticides over the past three decades, with use increasing each year as organophosphate use decreases (Power and Sudakin, 2007) . In 2013, pyrethroids accounted for the largest category (over 25%) of single substance, non-pharmaceutical exposure cases in the United States (Mowry et al., 2014) . Pyrethroids are also readily available to the general public in the form of household insecticidal sprays. Such widespread, unregulated use increases exposure and development of adverse disorders, with new evidence documenting pyrethroid bioaccumulation (Corcellas et al., 2015) and pyrethroid correlations with adverse neuronal outcomes (Oulhote and Bouchard, 2013; Viel et al., 2015; Richardson et al., 2015) . Alarming evidence from recent large-scale epidemiological studies identifies early life exposure to deltamethrin as a risk factor for autism spectrum disorders and a subunit with accessory b subunits (Goldin, 2001; Catterall, 2000) . The a subunit has 9 mammalian isoforms (Na v 1.1-Na v 1.9), each with distinct pharmacological and functional properties and varied distribution in excitable cells (Catterall et al., 2005; Cusdin et al., 2008; Shavkunov et al., 2013; Ogiwara et al., 2007) . Four of the nine isoforms are strongly expressed in the mammalian brainNa v 1.1, Na v 1.2, Na v 1.3, and Na v 1.6 (He and Soderlund, 2011; Catterall et al., 2005; Shavkunov et al., 2013; James et al., 2015; Leterrier et al., 2010) . Each a subunit is composed of four homologous domains with six transmembrane segments in each (Catterall, 2000; Catterall et al., 2005; O'Reilly et al., 2006) . Several residues critical for conferring pyrethroid sensitivity or resistance have been found in the IS6, IIS6, and IIIS6 segments, the IIS5 segment, and the IIS4-IIS5 linker region (O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005) , regions which are known to be involved in the inactivation of Na v channels (Catterall et al., 2005; Yarov-Yarovoy et al., 2001 , 2002 .
Pyrethroids are divided into two categories based on structureType I pyrethroids lack the a-cyano functional group found in the Type II category (Breckenridge et al., 2009) . Type I pyrethroid acute exposures are correlated with a T syndrome characterized by tremors while type II pyrethroid acute exposures correlate with a CS syndrome characterized by choreoathetosis with salivation (Breckenridge et al., 2009; Romero et al., 2015) . Furthermore, type I pyrethroids have a higher propensity for resting-state modification of Na v channels whereas type II pyrethroids have a higher affinity for the open state of a Na v channel (Tan and Soderlund, 2010; Breckenridge et al., 2009; He and Soderlund, 2011; McCavera and Soderlund, 2012) . These correlations are strong but not absolute, as some pyrethroids demonstrate activity associated with both categories of pyrethroid action (Tan and Soderlund, 2010; Breckenridge et al., 2009; He and Soderlund, 2011) . Deltamethrin is one example of a pyrethroid that can have both type I and type II activity. One of the more potent pyrethroids, deltamethrin contains an a-cyano group and has very strong activity associated with type II pyrethroids but simultaneously demonstrates some effects associated with type I pyrethroids (Tan and Soderlund, 2010; Breckenridge et al., 2009) . Previous studies have demonstrated that Na v 1.6 is sensitive to pyrethroid activity while other isoforms like Na v 1.2 are more resistant but not impervious (Tan and Soderlund, 2010; He and Soderlund, 2011; McCavera and Soderlund, 2012; O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005) . The V409 residue in cockroach sodium channel is involved on conferring natural sensitivity to pyrethroid activity, and when this residue is mutated to an isoleucine, pyrethroid resistance occurs (Oliveira et al., 2013) . The valine residue is conserved in human Na v 1.6 but is replaced by isoleucine in both Na v 1.1 and Na v 1.2 (Oliveira et al., 2013) . As Na v 1.2 and Na v 1.1 are phylogenetically closely related (Goldin, 2001; Catterall et al., 2005) , the presence of isoleucine at the cockroach 409 position in both isoforms suggests both channels may behave similarly to an acute pyrethroid exposure. As the primary Na v channel isoform expressed in fast-spiking GABAergic interneurons in the brain, Na v 1.1 plays an essential role in synchronizing brain activity during cognitive tasks which are disrupted in neurodevelopmental disorders, such as autism and schizophrenia (Berkowicz et al., 2016; Dong et al., 2016; Inan et al., 2016; Jiang et al., 2013; McNally et al., 2013) . On this premise we have hypothesized that the detrimental effects of early life exposure to deltamethrin might be reconciled with its brain toxicity for Na v 1.1 channels. To test this hypothesis, we studied the pharmacological activity of deltamethrin in Na v 1.1 channels expressed in heterologous cell systems using the well-studied Na v 1.6 as a comparative reference.
Here we present the action of deltamethrin on human Na v 1.1 or Na v 1.6 channels stably expressed in HEK293 cells. Our results show that deltamethrin induces significant modification of Na v 1.1 persistent and tail currents in its resting state with little reliance on channel opening to exert its effect. Compared with the betterstudied Na v 1.6, deltamethrin induced significant changes to persistent and tail currents that occur at lower concentrations in Na v 1.1 than in Na v 1.6. These findings suggest that Na v 1.1 is susceptible to deltamethrin modification, more amenable to modification at resting states, and sensitive to deltamethrin at lower concentrations than Na v 1.6, identifying Na v 1.1 as the preferential associative link to increased risk for neuropsychiatric disorders and early-life exposure to deltamethrin.
Materials and methods

Chemicals
Deltamethrin was dissolved in DMSO (Sigma, St. Louis, MO) to a stock concentration of 100 mM, aliquoted, and stored at À20 C for further use. Aliquots were then removed the day of experimentation, thawed, and added to the bath solution to make a final concentration of 0.01% DMSO and 10 mM deltamethrin if present. Deltamethrin was diluted further to 1 and 0.1 mM when mentioned, and DMSO controls were adjusted to 0.001% and 0.0001% final solution.
Cell culture
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless noted otherwise. HEK-293 cells stably expressing either human Na v 1.6 or human Na v 1.1 (gifts from Drs. Marzia Lecchi and Enzo Wanke, Università degli Studi di Milano-Bicocca, Milano, Italy) were maintained in medium composed of equal volumes of DMEM and F12 (Invitrogen, Carlsbad, CA) supplemented with 0.05% glucose, 0.5 mM pyruvate, 10% fetal bovine serum, 100 U/ml penicillin, 100 mg/mL streptomycin, and 500 mg/mL G418 (Invitrogen) for selection of stably transfected cells, and incubated at 37 C with 5% CO 2 , as previously described (Shavkunov et al., 2013) . The human Nav 1.6 and human Nav 1.1 HEK cell lines were validated through RT-PCR using the following primers specific to the particular human isoform: Nav1.1Fw TCTCTTGCGGCTATT-GAAAGAC, Nav1.1Rv GGGCCATTTTCGTCGTCATCT, Nav1.6Fw CCTTTCACCCCTGAGTCACTG, Nav1.6Rv AGGTCGCTGTTTGGCTTGG.
Electrophysiology
HEK-293 cells stably expressing either human Na v 1.1 or human Na v 1.6 were dissociated and re-plated at low-density. Recordings were performed at room temperature (20-22 C) using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA), and deltamethrin (10 mM, ABCam, Cambridge, MA) or DMSO (0.01% maximum final concentration, Sigma, St. Louis, MO) were added to the bath solution prior to transfer. Where mentioned, concentrations of 1 and 0.1 mM were used along with appropriate DMSO controls (0.001% and 0.0001% final concentration, respectively). Cells were allowed to rest in solution, exposed to the drug or vehicle, for approximately 30 min before beginning experiments. Recording continued after this period for one hour, resulting in 1.5 h of exposure to drugs. Borosilicate glass pipettes with resistances of 3-8 MV were made using a Narishige PP-83 vertical Micropipette Puller (Narishige International Inc., East Meadow, NY). The recording solutions were as follows: extracellular (mM): 140 NaCl, 3 KCl, 1 MgCl 2 , 1 CaCl 2 , 10 HEPES, 10 glucose, pH 7.3; intracellular: 130 CH 3 O 3 SCs, 1 EGTA, 10 NaCl, 10 HEPES, pH 7.3. Membrane capacitance and series resistance were estimated by the dial settings on the amplifier. Individual membrane capacitance ($9 pF average) was used to calculate current density, which allows for comparison with cells of all sizes, and cells exhibiting a series resistance of 25 MV or higher were excluded from analysis. Capacitive transients and series resistances were compensated electronically by 70-80%. Data were acquired at 20 kHz and filtered at 5 kHz prior to digitization and storage. All experimental parameters were controlled by Clampex 9 software (Molecular Devices) and interfaced to the electrophysiological equipment using a Digidata 1200 analog-digital interface (Molecular Devices). Voltage-dependent inward currents were evoked by depolarizations to test potentials between À60 mV and +70 mV from a holding potential of À70 mV. Steady-state (fast) inactivation of Na v channels was measured with a paired-pulse protocol. From the holding potential, cells were stepped to varying test potentials between À110 mV and 20 mV (prepulse) prior to a test pulse to À10 mV. Use-dependence was determined with a depolarization to À10 mV followed by a train of sub-threshold depolarizations to À30 mV at 10 Hz or 5 Hz frequency that terminates in another, final test pulse to À10 mV; this protocol was adapted from Dong and Priestley (2003) to assess use-dependence in absence of a continuous perfusion system, as traditional use-dependence protocols used for pyrethroid research did not fit with our current experimental model.
Electrophysiology data analysis
Current densities were obtained by dividing Na + current (I Na )
amplitude by membrane capacitance. Current-voltage relationships were generated by plotting current density as a function of the holding potential. Conductance (G Na ) is calculated by the following Eq. (1):
where I Na is the current amplitude at voltage V m , and E rev is the Na + reversal potential. Steady-state activation curves were derived by plotting normalized G Na as a function of test potential and fitted using the Boltzmann Eq. (2):
where G Na,Max is the maximum conductance, V a is the membrane potential of half-maximal activation, E m is the membrane voltage and k is the slope factor. For steady-state inactivation, normalized current amplitude (I Na /I Na,Max ) at the test potential was plotted as a function of prepulse potential (V m ) and fitted using the Boltzmann Eq. (3):
where V h is the potential of half-maximal inactivation and k is the slope factor. The percent of deltamethrin-modified channels were calculated using methods and equations as outlined in (Tatebayashi and Narahashi, 1994) and fit to the Hill equation. Usedependent peak current densities were taken from the final test pulse of the use-dependent protocol. Persistent, use-dependent current densities are taken as the mean current remaining after the transient current has ended and reached steady-state, again derived from the final test pulse. Tail currents are defined as the current that passes through remaining, opened Na v channels approximately 0.5 ms after termination of the depolarizing signal. Expressing tail currents over peak currents from the same depolarizing signal is termed the fraction of available current. Total charge was calculated by integrating the current signal after termination of the final test pulse and before the return to resting membrane potential. All modification values are calculated by expressing final test pulse values over the initial test pulse values. Data analysis was performed using Clampfit 9 software (Molecular Devices, USA) and Origin 8.6 software (OriginLab, Northampton, MA, USA).
Statistical analysis
Deltamethrin-induced effects were quantified and compared to DMSO controls for both isoforms. After testing for normality, a Student's t-test or a Mann-Whitney U test was used to make comparisons for parametric and non-parametric data, respectively. Statistical tests were performed with Origin 8.6 software (OriginLab, Northampton, MA, USA) and verified with SigmaPlot (Systat Software Inc., San Jose, CA, USA).
Results
Effects of deltamethrin on evoked properties
Effects of deltamethrin on peak transient current densities
We applied whole-cell patch-clamp electrophysiology to explore the action of deltamethrin on human Na v 1.1 or Na v 1.6 channels stably expressed in HEK293 cells. To assess the ability of deltamethrin to affect the resting state of Na v channels, we allowed HEK-Na v cells to rest in bath solution treated with one of three concentrations of DMSO (0.01, 0.001, or 0.0001% final concentration) or deltamethrin (10, 1, or 0.1 mM) for at least 30 min. A standard step-wise protocol was used to assess evoked properties after 30 min of bath incubation with drug, and representative traces of both protocol and results are depicted in Fig. 1A and B. Illustrated in Fig. 1 , deltamethrin did not significantly affect the peak transient current densities evoked at À10 mV in Na v 1.1 cells during a depolarizing pulse (167.5 AE 42.1 pA/pF, n = 14) relative to control values (115.0 AE 37.2 pA/pF, n = 9, p = 0.27, Fig. 1C ) at the highest concentration of deltamethrin. Similarly, Na v 1.6 control cells did not display a significant alteration of peak transient current densities at À10 mv (56.1 AE12.6 pA/pF, n = 10) when treated with 10 mM deltamethrin (29.3 AE 4.4 pA/pF, n = 20, p = 0.09, Fig. 1D ).
Effects of deltamethrin on window currents
Fitted curves of the voltage-dependence of activation (derived from protocols illustrated Fig. 1A and B) and steady-state inactivation, ascertained using a two-step protocol, are displayed in Fig. 1 . Na v 1.1 DMSO control cells exhibited a V 1/2 of activation of À22.6 AE 2.7 mV (n = 7) with a slope factor of 2.9 AE 0.42. Deltamethrin did not produce a significant change of V 1/2 of activation (À27.2 AE 6.7 mV, n = 12, p = 0.18, Fig. 1E ) or the slope factor (3.9 AE 0.60, p = 0.30). Na v 1.6 cells also did not show a significant alteration of V 1/2 of activation in DMSO control cells (-20 .7 AE 1.3 mV, n = 10) compared with deltamethrin cells (-23.8 AE 1.3 mV, n = 17, p = 0.14, Fig. 1F ). Na v 1.6 cells did, however, display a significantly altered slope factor between control cells (3.6 AE 0.3, n = 10) and deltamethrin cells (5.0 AE 0.3, n = 17, p = 0.01). Na v 1.1 DMSO control cells exhibited a V 1/2 of steady-state inactivation of À50.4 AE 5.0 (n = 8) with an accompanying slope factor of 5.9 AE 0.7. Deltamethrin did not produce a significant change in neither V 1/2 of steady-state inactivation (À53.9 AE 4.7, n = 13, p = 0.12, Fig. 1E ) nor the slope factor (5.2 AE 0.4, p = 0.75). Na v 1.6 channels did show a significant shift in the voltagedependence of steady-state inactivation with control cells demonstrating a V 1/2 of À56.6 AE 0.8 mV (n = 12) that was hyperpolarized to À64.5 AE 1.3 mV (n = 15, p < 0.001, Fig. 1F ). This alteration was not accompanied with a change in slope factor, as DMSO cells exhibited a k value of 5.9 AE 0.2 (n = 12) that was not statistically different from the deltamethrin average of 5.8 AE 0.3 (n = 15, p = 0.15). Activation and inactivation curves are superimposed in Fig. 1E and F in order to demonstrate the window currents (shaded regions) of each isoform with or without deltamethrin. Deltamethrin induces large increases to window currents in both isoforms, but the magnitude is larger in Na v 1.1. Furthermore, the isoforms demonstrate visually distinct shapes of their window currents, especially with respect to the inactivation curve. These data suggest that deltamethrin does not have a significant impact on the V 1/2 of activation or steady-state inactivation of peak transient currents in Na v 1.1 but does have a profound impact on the V 1/2 of persistent current activation. The same is not true for Na v 1.6, as deltamethrin induces significant alterations of steady-state inactivation in addition to generation of a persistent current. Visual inspection of window currents, however, reveals that deltamethrin has a profound effect on the channel opening in both isoforms, but such effects may vary between isoforms.
Effects of deltamethrin on persistent and tail current densities
Persistent and tail currents of both isoforms were studied using the same protocols shown in Fig. 1 , but with variable concentrations of deltamethrin and corresponding DMSO control. Derived from the same protocols portrayed in Fig. 1 , representative traces in Fig. 2A and B show persistent currents that remain after the fast transient has inactivated along with tail currents shown in the inset. In this study, persistent current is defined as the mean current over 20 ms measured 10 ms before the termination of the depolarizing potential. With this definition, 10 mM deltamethrin produced a significant potentiation of the persistent Na v 1.1 current densities (53.6 AE 9.5 pA/pF, n = 12) in relation to DMSO control values (10.2 AE 5.4, n = 4, p = 0.03, Fig. 2C ) at À20 mV. In a similar fashion, at À20 mV, Na v 1.6-encoded persistent current densities were also increased from DMSO control (À0.4 AE 0.6 pA/pF, n = 6) with 10 mM deltamethrin application (9.2 AE 2.4 pA/pF, n = 20, p < 0.01, Fig. 2D ). However, 1 mM deltamethrin maintains a significant potentiation of persistent current density exclusively in Na v 1.1 from À2.7 pA/pF (n = 3) in DMSO control cells to 17.6 pA/ pF (n = 20, p = 0.02, Fig. 2C ) with deltamethrin. Na v 1.6 persistent current densities are not significantly altered by deltamethrin at a 1 mM concentration (Fig. 2D) . Further parameters are summarized Fig. 1 . Representative traces of HEK-Na v 1.1 (A) or HEK-Na v 1.6 (B) cells in DMSO or deltamethrin-treated conditions in response to an evoked step-wise protocol (schematic under traces). With DMSO in black, Panels C and D depict a current-voltage relationship for Na v 1.1 and Na v 1.6, respectively, showing deltamethrin treatment in blue for Na v 1.1 and green for Na v 1.6. Summary bar graphs comparing peak current densities at À10 mV for all three concentrations are shown below the I-V graphs. Voltage-dependencies of activation and steady-state inactivation are depicted for Na v 1.1 (E) and Na v 1.6 (F); control curves are represented with dashed lines. Window currents are depicted where activation and steady-state inactivation curves overlap, which is indicated with shaded areas-gray for DMSO and colors for deltamethrin. Error bars indicate SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) in Table 1 . Both Na v 1.1 and Na v 1.6 cells treated with deltamethrin displayed a persistent current. However, not all DMSO cells displayed persistent current, and those were excluded in the comparison. Tail current densities increased with voltage in DMSO control cells in a relatively linear fashion, but the slope of the voltage-dependency of the Na v 1.1 tail currents, derived from the I-V curve ( Fig. 2C and E) are significantly altered with deltamethrin treatment at both 10 and 1 mM. While DMSO control cells' tail current densities steadily increased to peak at maximum positive voltage, deltamethrin-treated Na v 1.1 cells displayed a shifted peak that occurred at À10 mV and was followed with slight attenuation at higher voltages (Fig. 2E ) in the two higher concentrations. Na v 1.6 cells did not mirror the slope effect observed in Na v 1.1 cells at any concentration. Taken at the observed peak of À10 mV in Na v 1.1 cells, DMSO control cells exhibited a tail current density of 21.4 AE 6.3 pA/pF (n = 9) that was significantly increased to 114.8 AE 17.9 pA/pF (n = 14, p < 0.001, Fig. 2E ) with deltamethrin treatment. Na v 1.6 also demonstrated significant potentiation of tail currents from 5.9 AE 1.5 pA/pF (n = 10) in DMSO control cells to 25.1 AE 4.1 pA/pF (n = 20, p < 0.001, Fig. 2F ) with 10 mM deltamethrin At 0.01% DMSO, Na v 1.1 control cells exhibited a tail current density of 1.2 pA/pF (n = 3) that was potentiated to 77.8 pA/pF (n = 9, p = 0.04) with 1 mM deltamethrin, and this potentiation was not observed in Na v 1.6 cells with the same concentration of deltamethrin ( Fig. 2E and F) . It was found that DMSO has a slight effect on current densities in Na v 1.1, and therefore we could not generate a canonical dose-response curve. These data indicate that deltamethrin does not have a major impact on transient current densities in either isoforms, but it does have a sizeable effect on persistent and tail current magnitudes and tail current shape in both isoforms at 10 mM. Reducing this concentration to 1 mM abolished significant effects in Na v 1.6 but not in Na v 1.1; however, all significant effects do disappear at 0.1 mM deltamethrin (Fig. 2C-F ). These data suggest that while deltamethrin has profound effects on both Na v 1.1 and Na v 1.6 in the resting state, and that Na v 1.1 is more sensitive to resting-state modification carried out by deltamethrin at lower concentrations than Na v 1.6. Applying the same method used for peak current densities to persistent current densities, the voltage-dependence of persistent current was also determined. In Na v 1.1 cells, a robust and significant hyperpolarizing shift was detected in the V 1/2 of persistent current activation of deltamethrin cells (À34.7 AE 1.1 mV, n = 16, p < 0.001, Table 1 ) compared to DMSO control cells (À22.8 AE 1.4 mV, n = 4). Changes to V 1/2 were also reflected in the slope factor for Na v 1.1 cells, as the DMSO average slope factor was 6.5 AE 0.9 (n = 4) and changed to 2.8 AE 0.3 (n = 16, p < 0.001) in deltamethrin cells. In Na v 1.6 cells, no DMSO control cells exhibited persistent currents with a sigmoidal voltage relationship, and therefore we could not generate an activation curve for this group. Deltamethrin-treated Na v 1.6 cells did show a V 1/2 of activation of persistent current of À26.8 AE 1.4 mV (n = 9, data not shown). Additional analysis performed by normalizing persistent sodium currents to DMSO transient peak currents (Fig. 3A and B) revealed that deltamethrin had a stronger effect on Nav1.1 than Nav1.6 (at voltage step À10 mV-57.4 AE 8.8% in Nav1.1 cells, n = 17 versus 14.5 AE 4.2% in Nav1.6 cell, n = 20; p < 0.0005 with Student t-test).
Finally, the maximum percentage of deltamethrin-modified channels (M max ) and K d values were calculated using equation from (Tatebayashi and Narahashi, 1994) and fitting with Hill equation, respectively (Fig. 3C) . At 10 mM of deltamethrin M max was 56.05 AE 5.7% for Nav1.1 (n = 19) versus 33.4 AE 4.4% for Nav1.6 (n = 14), a difference that was statistically significant (p < 0.005 with Student, t-test). Differences in M max from the two isoforms were mirrored by K d (0.49 mM for Nav1.1 versus 0.92 mM for Fig. 3 . Current-voltage relationship for Na v 1.1 (A) and Na v 1.6 (B) depicting DMSO control peak currents (black squares) and deltamethrin persistent currents (colored circles). Concentration-dependent effect of deltamethrin as percentage of deltamethrin modified channels shown in C, with Na v 1.1 represented in blue and Na v 1.6 in green. Error bars indicate SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Tail current density, F) Peak current density modification, G) Tail current density modification, H) Persistent current density, I) Fraction of available current, J) Peak current modification, K) Total charge. Error bars indicate SEM. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) Nav1.6), reinforcing the notion that Na v 1.1 channels are more susceptible to deltamethrin modification than Nav1.6
Effects of deltamethrin on use-dependent properties
Previous research has established that deltamethrin has high affinity for the open (active) state of Na v channels (He and Soderlund, 2011; McCavera and Soderlund, 2012; Dong and Priestley, 2003 ), and we therefore tested this aspect of function as well. Use-dependent activity of deltamethrin was assessed with two separate test pulses to À10 mV prior to or after a train of subthreshold depolarizations to À30 mV at a rate of 10 or 5 Hz, and representative traces of the protocols and their results are shown in Fig. 4 . No major differences were observed between stimulation frequency groups, therefore, henceforth, all values mentioned in this text will refer to the 5 Hz protocol. All values are summarized in Table 2 and illustrated in Fig. 4 . For Na v 1.1, control cells displayed a peak transient current density of 101.6 AE 26.6 pA/pF (n = 10, Fig. 4D ), and expression of this value over the value obtained from the initial test pulse indicates that these cells demonstrate a 101.6 AE 2.8% alteration of use-dependent, peak, transient current densities (Fig. 4F) . Deltamethrin-exposed cells displayed a final peak current density of 121.8 AE 24.2 pA/pF (n = 17) that was not significantly different from DMSO control (Fig. 4D) . This value was a 99.9 AE 4.4% change from initial test values, which is not significantly different from DMSO control (Fig. 4F) . In Na v 1.6 cells, DMSO control cells exhibited a peak current density of 42.1 AE12.5 pA/pF (n = 11) while deltamethrin peak, transient current densities were 25.5 AE 4.3 pA/pF (n = 19), which was not a statistically significant change (Fig. 4D) . However, Na v 1.6 cells did show a significant ability to undergo use-dependent change, as DMSO cells displayed current densities that are 96.5 AE 2.4 (n = 11) while deltamethrin-treated cells displayed a 120.6 AE 8.0% (n = 19, p < 0.001) increase from their initial values (Fig. 4F) . These data indicate that neither Na v channel isoform displays a usedependent effect on peak current densities relative to DMSO controls, but Na v 1.6 does display a significant use-dependent potentiation of peak current densities after a train of depolarizing potentials.
Applying the same definition outlined in Section 3.1.2 to the use-dependent test pulses in our protocol, Na v 1.1 DMSO control cells displayed small degrees of persistent current densities of À1.1 AE 2.0 pA/pF (n = 10) that represent a 67.4 AE 27.4% alteration of initial values. Deltamethrin significantly potentiated persistent current to 60.5 AE 7.6 pA/pF (n = 17, p < 0.001, Fig. 4H ), but the degree of this alteration was not significantly different at 83.6 AE 10.7% (Fig. 4J ). For Na v 1.6, persistent current densities were À3.5 AE 1.8 pA/pF (n = 12) in DMSO control cells, and deltamethrin application significantly potentiated the persistent current to 11.8 AE 2.5 pA/pF (n = 19, p < 0.001, Fig. 4H) . In DMSO cells, the final persistent currents were 136.7 AE 36.0% (n = 11) of their initial values while deltamethrin cells exhibited a significantly larger increase in persistent current at 253.8 AE 50.8% (n = 18, p = 0.01, Fig. 4J ) of the initial values. These data suggest that while deltamethrin induces substantial and significant persistent current in both Na v isoforms, only Na v 1.6 demonstrates reliance upon channel use in order to exert or enhance its effect. This observation may indicate that Na v 1.1 is more heavily modified by deltamethrin during its resting state than Na v 1.6.
Deltamethrin affected tail currents in a similar fashion. Na v 1.1 DMSO control cells displayed a tail current density of 17.9 AE 3.4 pA/ pF (n = 10) which was a 107.7 AE4.4% change from initial test pulse values. These densities were significantly potentiated to 147.8 AE 18.1 (n = 17, p < 0.001, Fig. 4E ) with deltamethrin treatment, and this potentiation represented a 127.1 AE 9.8% (n = 17, Fig. 4G ) change from initial values, which was not statistically significant. Na v 1.6 DMSO controls cells displayed tail current densities of 14.3 AE 3.6 pA/pF (n = 12) while deltamethrin-treated cells exhibited tail current densities of 45.5 AE 5.7 pA/pF (n = 20, p < 0.001, Fig. 4E ) that were significantly larger. Furthermore, the DMSO-exposed cells demonstrated a 107.8 AE 4.6% (n = 12) change from initial values, and deltamethrin treatment lead to a significantly larger degree of change of 131.0 AE 5.1% (n = 20, p < 0.001, Fig. 4G ). Expressing tail current densities over their paired transient peak current density was used as a measure of inactivation-resistant Na v channels and was termed fraction of available current. Na v 1.1 control cells displayed a fraction of available current of 0.27 AE 0.06 (n = 9), and deltamethrin treatment significantly increased this fraction to 1.49 AE 0.16 (n = 17 Fig. 4I) . Similarly, Na v 1.6 control cells exhibited a fraction of available current of 0.10 AE 0.28 (n = 11) that was significantly increased in cells treated with deltamethrin to 2.12 AE 0.26 (n = 19, p < 0.01, Fig. 4I ). Collectively, these data indicate that deltamethrin significantly increases the inactivation resistance of both Na v isoforms; however, significant and usedependent changes occur exclusively in Na v 1.6 whereas any significant effects created by deltamethrin application to Na v 1.1 channels likely occurred during rest and not during channel opening. Because of the high persistence of the sodium current induced by deltamethrin, we were unable to determine the time-constant of decay of the tail currents and therefore measured total flux. Na v 1.1 control cells exhibited a total flux of 1087.4 AE 389.2 nC (n = 10), and deltamethrin treatment significantly increased this total flux to 28143.5 AE 3745.8 nC (n = 17, p < 0.001, Fig. 4K ). For Na v 1.6, DMSO cells displayed a total charge of 747.3 AE 218.5 nC (n = 12) that was significantly increased to 6080.3 AE 805.0 nC (n = 20, p < 0.001, Fig. 4K ). Deltamethrin treatment significantly potentiated the amount of charge flux for each isoform, yet its effect on Na v 1.1 channels is larger than Na v 1.6. These observations suggest that while deltamethrin exerts more use-dependent changes on Na v 1.6 than Na v 1.1, its effect on the latter is still profound.
Discussion
This study represents the first description of deltamethrin action on the Na v 1.1 a subunit isoform stably expressed in HEK293 cells. We acknowledge that our use of a subunits without accompanying b subunits may not be reflective of several native mammalian Na v channel (Hartshorne and Catterall, 1984; Wildburger et al., 2015) . Nevertheless, knowledge of naked a subunit behavior will inform future studies of Na v channels expressed with b subunits. Past studies have postulated that the residue corresponding to V409 in cockroach sodium channel is critical for conferring pyrethroid resistance or susceptibility (O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005; Du et al., 2011; Vais et al., 2000) . In the Na v 1.2 isoform, it is believed that an isoleucine at this position renders the channel more resistant to pyrethroid modification (O'Reilly et al., 2006; Oliveira et al., 2013) , and the presence of valine at this position in the Na v 1.6 isoform is critical for relatively increased susceptibility to pyrethroids compared to Na v 1.2 (O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005; Du et al., 2011; Vais et al., 2000) . We found that deltamethrin did not produce a significant change in peak current densities of neither Na v 1.1 nor Na v 1.6 a subunits expressed in HEK293 cells. These findings are consistent with similar results with other Na v isoforms in which pyrethroids alter the ability of a Na v channel to inactivate without affecting peak current densities Soderlund, 2010, 2009; Chinn and Narahashi, 1986; He and Soderlund, 2011; McCavera and Soderlund, 2012) . We found that deltamethrin did not significantly influence voltage dependence of activation for either isoform; however, a significant shift in slope was detected only for Na v 1.6. An approximately 8 mV hyperpolarizing shift in the voltage-dependence of steady-state inactivation was detected only in Na v 1.6 with no significant change to slope. For Na v 1.1, values for V 1/2 of activation and steady-state inactivation are consistent with established values of Na v 1.1 in HEK293 cells (Qiao et al., 2014) with minor differences attributable to varied culture protocols, reagents, and our use of DMSO as a control. Deltamethrin did not produce a significant change in the V 1/2 for activation, which is not consistent with previous studies demonstrating that deltamethrin hyperpolarizes the V 1/2 for both activation and steadystate inactivation Soderlund, 2010, 2009; He and Soderlund, 2011) . Our values and outcomes for these parameters in Na v 1.6 differ somewhat from other studies' findings (Tan and Soderlund, 2010; He and Soderlund, 2011; McCavera and Soderlund, 2012) , a disparity that might be attributed to species differences. Compared with HEK293 cells prepared similarly to ours with expression of rat Na v 1.6, our human Na v 1.6 appears to be less sensitive to deltamethrin modification than the rat Na v 1.6 used in the same HEK293 expression system (He and Soderlund, 2015) . Without varying methods of expression, it is then likely that the differences seen between rat and human Na v 1.6 stem from differences between the two species. Inter-species differences in pyrethroid sensitivity have been demonstrated before for Nav1.3 (Tan and Soderlund, 2009 ), thus it is important to consider that rodent models of deltamethrin activity may not sufficiently represent what occurs in humans. Inspection of window currents suggests that Na v 1.1 is still affected by deltamethrin application, but these changes may not best be reflected by peak currents. In this context, Na v 1.6 peak current densities are more sensitive to deltamethrin modification.
Both Na v 1.1 and Na v 1.6 persistent current densities were significantly potentiated with 10 mM deltamethrin, but only Na v 1.1 demonstrated significant potentiation when deltamethrin was reduced to 1 mM. These findings are consistent with previous studies indicating that deltamethrin has a potent impact on persistent (or "late") currents in Na v 1.6 channels (Tan and Soderlund, 2010; Soderlund, 2011, 2015) . It was, however, surprising to find that a lower deltamethrin concentration was sufficient to effect significant change in Na v 1.1 and not Na v 1.6, which was not predicted based on comparisons with other isoforms (Catterall et al., 2005; O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005; Du et al., 2011) . Furthermore, the voltage-dependence of this persistent current was hyperpolarized by $10 mV in Na v 1.1 cells treated with deltamethrin. Such a major shift in favor of more hyperpolarized potentials lying closer to Na v voltage thresholds could explain the larger window currents for Na v 1.1 cells. Na v 1.6 cells treated with deltamethrin also showed an induction of persistent current, but the associated control values were not sigmoidal in nature and could not be fitted. We also observed that voltage-dependent tail current densities for both isoforms were potentiated with 10 mM deltamethrin application, but again, only Na v 1.1 retained a significant potentiation at 1 mM deltamethrin. Furthermore, Na v 1.6 tail current densities follow a relatively linear pattern in their current-voltage relationship that places the maximum current densities with the maximum voltage at +40 mV, but Na v 1.1 displays a shifted peak occurring at À10 mV that tapers and stabilizes with increasing voltage. It is uncertain what mechanism underlies this shift to À10 mV or the differences in shape, but this curve is similar to the tail currents induced by tefluthrin (a type I pyrethroid) as reported by He and Soderlund (2011) . Additionally, we were only able to detect significant changes in Na v 1.6 cells at 10 mM deltamethrin, which is markedly higher than the $0.1 mM threshold identified in He and Soderlund (2015) . This contradiction may be a result of the transient transfection used in (He and Soderlund, 2015) as opposed to our cell line that stably expresses a Na v isoform, as the former yielded higher current magnitudes that could have allowed for more sensitive assays. Additionally, it should be noted that our experiments employed a static bath design, which differed from other studies that typically use perfusion-based methods. While this does limit our direct comparisons to results from other studies because of varying experimental designs, there are still several comparisons that can be inferred even among varying experimental conditions. Nonetheless, within the context of our experiments, Na v 1.1 is more sensitive to resting deltamethrin modification of persistent and tail currents than Na v 1.6. In use-dependent protocols, neither isoform demonstrated a change in peak current density with deltamethrin treatment, but Na v 1.6 did show a significant increase in the degree of change induced by a train of depolarizations. This is consistent with previous studies demonstrating a use-dependent increase of Na v 1.6 function (Tan and Soderlund, 2010; Soderlund, 2011, 2015) . Deltamethrin did produce significant increases to both persistent currents and tail currents in both isoforms, which is consistent with previous studies of Na v 1.6 Soderlund, 2010, 2009; He and Soderlund, 2011) . However, no value was accompanied with a significant% change from the initial test pulse in Na v 1.1 recordings, indicating that enhancement of persistent and tail currents occurred prior to recording during the incubation phase and is not use-dependent. Deltamethrin did produce a significant and use-dependent increase of the fraction of available current for both isoforms, indicating deltamethrin exposure results in an increased population of inactivation-resistant Na v 1.1 and Na v 1.6 channels, which is seen in other isoforms as well Soderlund, 2010, 2009; He and Soderlund, 2011; McCavera and Soderlund, 2012) . Due to the robust persistence of currents induced by deltamethrin exposure, the time constant of decay was not able to be determined. However, using the area under the curve to indicate total charge flux, we found that deltamethrin significantly increased the amount of Na + able to cross the membrane in a use-dependent manner, which is consistent with similar measures in other studies of Na v channel isoforms Soderlund, 2010, 2009; He and Soderlund, 2011; McCavera and Soderlund, 2012) . We found the same effect in Na v 1.6, but the magnitude of charge was much lower. Taken together, these data indicate that Na v 1.6 channels are much more amenable to use-dependent alteration than their Na v 1.1 counterparts. Na v 1.1 channels do show significant changes in persistent and tail currents when compared to DMSO control, but when compared with naïve channel prior to depolarization trains there is no difference, indicating these changes could have occurred during incubation and are not likely use-dependent.
In conclusion, our results indicate that the Na v 1.1 a subunit isoform is vulnerable to deltamethrin exposure at concentrations equivalent to or lower than concentrations needed to effect similar changes in Na v 1.6, which was not predicted based on phylogenetic similarity to Na v 1.2 (Catterall et al., 2005; Oliveira et al., 2013) and the presence of an isoleucine at the 409 (cockroach) residue (O'Reilly et al., 2006; Oliveira et al., 2013; Tan et al., 2005; Du et al., 2011) . Similar to other isoforms, deltamethrin effected usedependent enhancement of the fraction of available current and total charge flux in both Na v 1.1 and Na v 1.6 Soderlund, 2010, 2009; He and Soderlund, 2011; McCavera and Soderlund, 2012) . Persistent and tail currents were potentiated with deltamethrin exposure at a lower concentration than needed for similar effects in Na v 1.6, but repeated depolarizing trains only enhanced Na v 1.6 modification, which indicates most channel modification of Nav1.1 occurs at rest without use-dependent enhancement. It is possible that the addition of Na v b subunits could alter the behavior of these channels and possibly confer usedependence on one or both of the channels, bringing them in line with other studies (Tan and Soderlund, 2010; Soderlund, 2011, 2015) . A previous study (He and Soderlund, 2011) indicated that deltamethrin, a type II pyrethroid, enhances tail currents and delays the onset of inactivation in a use-dependent manner while tefluthrin, a type I pyrethroid, induced more resting-state modification than deltamethrin. Considering that deltamethrin demonstrates some characteristics of type I pyrethroids, as indicated in (Breckenridge et al., 2009) , the resting-state bias for Na v 1.1 observed in this study may be a result of this overlap of characteristics. Therefore, various Na v isoforms may be biased toward either resting-state or open-state modification depending on where the pyrethroid falls in the continuum between type I and type II characteristics, and as a result, they favor one type of pyrethroid over the other. If correct, this hypothesis suggests that a pyrethroid associated primarily with type I characteristics, like permethrin (Breckenridge et al., 2009) , would induce resting modification of Na v 1.1 while a pyrethroid that primarily demonstrates type II characteristics, such as l-cyhalothrin (Breckenridge et al., 2009) would effect little to no use-dependent modification. Conversely, Na v 1.6 should be comparatively more amenable to modification by a type II pyrethroid like l-cyhalothrin rather than a type I pyrethroid such as permethrin. Taken together, our data show that Na v 1.1 is susceptible to deltamethrin modification at lower concentrations than for Na v 1.6, but this susceptibility stems from a bias toward resting modification over use-dependent, demonstrating that Na v isoforms have differential responses to the same pyrethroid treatment. With significant susceptibility to deltamethrin, Nav1.1 might be the biological link between early-life exposure to pyrethroids, impaired function of inhibitory fast-spiking interneurons (where Nav1.1 is abundantly expressed) and increased risk for neurodevelopmental disorders in the human population (Viel et al., 2015; Richardson et al., 2015; Ogiwara et al., 2007; Berkowicz et al., 2016; Dong et al., 2016; Inan et al., 2016; Jiang et al., 2013; McNally et al., 2013; Catterall et al., 2008; Lee et al., 2015) . Future studies profiling activity of a broader spectrum of pyrethroids against Nav1.1 channels might generate improved EPA guidelines to prevent early-life exposure toxicity of pesticides.
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